

Urabrelimab

Cat. No.:	HY-P99533
CAS No.:	2249722-58-3
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction ^[1] .
In Vitro	Urabrelimab (SRF231) promotes macrophage-mediated phagocytic clearance of several hematologic primary tumor samples and cell lines in vitro. Urabrelimab increases phagocytosis of Raji tumor cell line targets with an EC ₅₀ of ~300 ng/mL ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Urabrelimab (SRF231) administration leads to profound tumor growth inhibition in models of multiple myeloma, diffuse large B cell lymphoma and Burkitt's lymphoma as a single agent and in combination with opsonizing antibodies. In the Raji xenograft model, single agent therapy leads to 112% tumor growth inhibition ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Holland P M, et al. CD47 monoclonal antibody SRF231 is a potent inducer of macrophage-mediated tumor cell phagocytosis and reduces tumor burden in murine models of hematologic malignancies. 2016.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA